HUNTSVILLE, ALABAMA / ACCESS Newswire / November 13, 2025 / Curiteva, Inc. a privately held manufacturing and technology company, proudly…
THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A…
Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…
Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™…
Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response…
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819,…
- Combined transactions will strengthen balance sheet and reduce outstanding debt by more than 90% - - $6 million PIPE financing…
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders,…
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders,…